Comparison of Outcome in Patients With ST-Elevation Versus Non–ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry)

Abbott, J. Dawn; Ahmed, Hanna N.; Vlachos, Helen; Selzer, Faith; Williams, David O.

doi:10.1016/j.amjcard.2007.02.083

Cited by 132 publications

(88 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13,14 Others have found that STEMI has been associated with a higher likelihood of in-hospital death. 15 It also has been suggested that NSTEMI patients do worse than STEMI patients because of differences in baseline characteristics and decreased use of therapies in the acute setting. 16,17 Use of biomarker determination of MI has evolved over the duration of the ARIC Study.…”

Section: Severity Indicatorsmentioning

confidence: 99%

Declining Severity of Myocardial Infarction From 1987 to 2002

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Severity Indicatorsmentioning

confidence: 99%

Declining Severity of Myocardial Infarction From 1987 to 2002

et al. 2009

View full text Add to dashboard Cite

show abstract

“…However, patients with NSTEMI often have a more longstanding history of ischaemic heart disease, increased prevalence of comorbidities, smaller acute ischaemic burden, and a different prognosis from those with STEMI. (24,25) …”

Section: Resultsmentioning

confidence: 99%

The prognostic value of left atrial function assessed by TDI after myocardial infarction (comparison between ST and non ST segment elevation myocardial infarction)

Salama¹

2017

jmscr

View full text Add to dashboard Cite

Aim: The aim of this study is to assess the predictive value of LA function by TDI for assessment of the prognosis of patients with ST and non ST segment elevation (NSTE) myocardial infarction (MI). Methods and Results Conclusion: Assessment of LA function by TDI is a strong parameter in the prognosis and prediction of cardiac events in patients with ST and non ST segment elevation (NSTE) myocardial infarction (MI). IntroductionIt is clear that studies of LA function provide new insights into the contribution of LA performance to cardiovascular disease and are promising tools for predicting cardiovascular events in a wide range of patient populations.

show abstract

“…It is well recognized that the short-term and long-term prognoses of STEMI patients are different from those in non-STEACS patients. 26,27) Therefore, there were some shortcomings with regards to combining the two groups. Second, the subjects in this study were STEMI patients who had undergone PCI treatment, and intervention therapy had progressed to an era of drug-eluting stents with more advanced surgical techniques.…”

Section: Discussionmentioning

confidence: 99%

Interleukin-18 Levels on Admission Are Associated With Mid-Term Adverse Clinical Events in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

et al. 2010

View full text Add to dashboard Cite

SummaryThe long-term prognostic value of interleukin (IL)-18 in patients with ST-segment elevation acute myocardial infarction (STEMI) has been conflicting. Thus, the purpose of this study was to test whether the level of interleukin-18 measured on admission can predict long-term adverse clinical events in patients with STEMI who were undergoing percutaneous coronary intervention (PCI).We recruited 288 consecutive STEMI patients (210 men, average age [71.42 ± 10.32] years) with onset < 6 hours who were undergoing primary PCI, and 148 age-and gender-matched control subjects. Plasma levels of IL-18 were measured by enzyme-linked immunosorbent assay (ELISA) in all subjects. The patients with STEMI were then followed prospectively over 434 days (range, 0 to 642 days) for the occurrence of composite major adverse clinical events (MACE) (cardiac mortality, recurrent myocardial infarction, or readmission due to advanced heart failure). Patients with STEMI exhibited higher levels of plasma IL-18 (P < 0.001) compared with the control subjects. Positive correlations between IL-18 and cardiac troponin-I (cTnI ) (r = 0.353, P = 0.0004) and IL-18 and high-sensitivity C-reactive protein (hs-CRP) (r = 0.420, P < 0.001) were observed by Spearman's correlations analysis. Logistic regression analysis demonstrated that IL-18 ≥ 450 pg/mL (OR 10.854, 95% CI 2.328 to 50.594, P < 0.0001) was a significant independent predictor of composite MACE at 60 days. Cox regression analysis demonstrated that high plasma IL-18 levels were not correlated with the occurrence of long-term composite MACE.The level of plasma IL-18 on admission may predict 60-day adverse clinical outcome, but not the long-term adverse clinical events in patients with STEMI undergoing PCI, and may be useful for mid-term risk stratification. (Int Heart J 2010; 51: 75-81) Key words: Coronary heart disease, ST-segment elevation acute myocardial infarction, Percutaneous coronary intervention, Cytokine, Interleukin-18 (IL-18), Prognosis A therosclerosis is widely accepted as a chronic inflammatory disease initiated by different vascular and extravascular sources. 1) On the site of the atherosclerotic plaque, the intima is infiltrated with activated macrophages and T lymphocytes, both of which produce and secrete cytokines to drive the inflammatory process. 2)Acute coronary syndrome (ACS) is characterized by ruptured atherosclerotic coronary plaque with superimposed thrombosis, which constitutes the most common, general, and pathological background of ACS. A previous study has also demonstrated that inflammatory mechanisms play an essential role in triggering ACS. 3)Interleukin-18 (IL-18) is a multifunctional proinflammatory cytokine which can induce T lymphocytes and natural killer cells to produce interferon-γ.4) It was originally named interferon-γ inducing factor, 5) and was then later renamed IL-18 because it was found to have many other biological effects. Recent evidence has indicated that IL-18 is closely related to the progress of atherosclerotic plaques and the inst...

show abstract

Comparison of Outcome in Patients With ST-Elevation Versus Non–ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry)

Cited by 132 publications

References 22 publications

Declining Severity of Myocardial Infarction From 1987 to 2002

Declining Severity of Myocardial Infarction From 1987 to 2002

The prognostic value of left atrial function assessed by TDI after myocardial infarction (comparison between ST and non ST segment elevation myocardial infarction)

Interleukin-18 Levels on Admission Are Associated With Mid-Term Adverse Clinical Events in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Contact Info

Product

Resources

About